Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy-Reference-Cited by-同舟云学术

Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy

Published:2020-06 Issue:21 Volume:75 Page:2649-2660
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Ho Carolyn Y.,Mealiffe Matthew E.,Bach Richard G.,Bhattacharya Mondira,Choudhury Lubna,Edelberg Jay M.,Hegde Sheila M.,Jacoby Daniel,Lakdawala Neal K.,Lester Steven J.,Ma Yanfei,Marian Ali J.,Nagueh Sherif F.,Owens Anjali,Rader Florian,Saberi Sara,Sehnert Amy J.,Sherrid Mark V.,Solomon Scott D.,Wang Andrew,Wever-Pinzon Omar,Wong Timothy C.,Heitner Stephen B.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference39 articles.

1. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC);Elliott;Eur Heart J,2014

2. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance;Maron;J Am Coll Cardiol,2009

3. The role of super-relaxed myosin in skeletal and cardiac muscle;McNamara;Biophysic Rev,2015

4. Ablation of cardiac myosin binding protein-C disrupts the super-relaxed state of myosin in murine cardiomyocytes;McNamara;J Mol Cell Cardiol,2016

Cited by 200 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mavacamten in hypertrophic obstructive cardiomyopathy: Prospects for AI integration and mitigating healthcare disparities;Current Problems in Cardiology;2024-11

2. Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response;Journal of the American Heart Association;2024-09-03

3. Comparison of Drug Therapy Efficacy in Patients With Hypertrophic Cardiomyopathy: A Network Meta-Analysis;The American Journal of Cardiology;2024-09

4. Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration;CPT: Pharmacometrics & Systems Pharmacology;2024-08-13

5. Efficacy and safety of Mavacamten for symptomatic Hypertrophic cardiomyopathy – an updated Meta-Analysis of randomized controlled trials;IJC Heart & Vasculature;2024-08